AVITA Medical, Inc. (RCEL): Price and Financial Metrics
GET POWR RATINGS... FREE!
RCEL POWR Grades
- Sentiment is the dimension where RCEL ranks best; there it ranks ahead of 88.51% of US stocks.
- The strongest trend for RCEL is in Quality, which has been heading down over the past 178 days.
- RCEL ranks lowest in Momentum; there it ranks in the 18th percentile.
RCEL Stock Summary
- For RCEL, its debt to operating expenses ratio is greater than that reported by only 4.53% of US equities we're observing.
- RCEL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 9.83% of US stocks.
- With a year-over-year growth in debt of -66.67%, AVITA MEDICAL INC's debt growth rate surpasses just 3.41% of about US stocks.
- If you're looking for stocks that are quantitatively similar to AVITA MEDICAL INC, a group of peers worth examining would be GLBE, SONX, FLYW, EGRX, and WRAP.
- Visit RCEL's SEC page to see the company's official filings. To visit the company's web site, go to www.avitamedical.com.
RCEL Valuation Summary
- RCEL's price/sales ratio is 9; this is 373.68% higher than that of the median Healthcare stock.
- Over the past 42 months, RCEL's price/sales ratio has gone down 98.7.
Below are key valuation metrics over time for RCEL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RCEL | 2023-03-17 | 9.0 | 4.0 | -12.7 | -12.0 |
| RCEL | 2023-03-16 | 9.0 | 4.0 | -12.7 | -12.0 |
| RCEL | 2023-03-15 | 9.0 | 4.0 | -12.7 | -12.0 |
| RCEL | 2023-03-14 | 8.9 | 3.9 | -12.5 | -11.9 |
| RCEL | 2023-03-13 | 8.5 | 3.8 | -12.0 | -11.4 |
| RCEL | 2023-03-10 | 8.9 | 4.0 | -12.6 | -12.0 |
RCEL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RCEL has a Quality Grade of D, ranking ahead of 9.85% of graded US stocks.
- RCEL's asset turnover comes in at 0.314 -- ranking 128th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows RCEL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.314 | 0.810 | -5.438 |
| 2020-12-31 | 0.239 | 0.845 | -0.901 |
| 2020-06-30 | 0.335 | 0.837 | -3.514 |
| 2019-06-30 | 0.292 | 1.195 | -1.429 |
| 2019-06-30 | 0.550 | 1.103 | -1.428 |
| 2019-06-30 | 0.292 | 1.195 | -1.429 |
RCEL Price Target
For more insight on analysts targets of RCEL, see our RCEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $40.60 | Average Broker Recommendation | 1.3 (Strong Buy) |
RCEL Stock Price Chart Interactive Chart >
RCEL Price/Volume Stats
| Current price | $13.49 | 52-week high | $14.75 |
| Prev. close | $13.21 | 52-week low | $4.41 |
| Day low | $13.27 | Volume | 127,366 |
| Day high | $13.83 | Avg. volume | 142,786 |
| 50-day MA | $10.53 | Dividend yield | N/A |
| 200-day MA | $7.13 | Market Cap | 341.24M |
AVITA Medical, Inc. (RCEL) Company Bio
AVITA Medical, Inc. operates as a medicine company. The Company focuses on the development and commercialization of therapies to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. AVITA Medical serves customers worldwide.
Latest RCEL News From Around the Web
Below are the latest news stories about AVITA MEDICAL INC that investors may wish to consider to help them evaluate RCEL as an investment opportunity.
AVITA Medical Appoints New Non-Executive Member to the Board of DirectorsVALENCIA, Calif. and MELBOURNE, Australia, March 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Cary Vance to its Board of Directors, effective April 1, 2023. Mr. Vance has over 25 years of extensive leadership experience with commercial and operational expertise in the health |
What Makes Avita Medical Inc. (RCEL) a Good Fit for 'Trend Investing'Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
How Much Upside is Left in Avita Medical Inc. (RCEL)? Wall Street Analysts Think 27.42%The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
AVITA Medical to Present at the TD Cowen 43rd Annual Health Care ConferenceVALENCIA, Calif. and MELBOURNE, Australia, March 02, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that Jim Corbett, Chief Executive Officer, will present at the TD Cowen 43rd Annual Health Care Conference in Boston on Tuesday, March 7, 2023, at 9:10 a.m. Eastern Time. A live audio webcast of the p |
Here's Why 'Trend' Investors Would Love Betting on Avita Medical Inc. (RCEL)Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
RCEL Price Returns
| 1-mo | 41.26% |
| 3-mo | 100.45% |
| 6-mo | 140.04% |
| 1-year | 74.29% |
| 3-year | -40.64% |
| 5-year | 186.11% |
| YTD | 104.39% |
| 2022 | -44.91% |
| 2021 | -35.52% |
| 2020 | -59.16% |
| 2019 | 712.50% |
| 2018 | 4.67% |
Loading social stream, please wait...